--- license: llama3.1 base_model: meta-llama/Llama-3.1-8B language: - en pipeline_tag: text-generation tags: - medical - clinical - nigeria - healthcare - africa - llama - global-health --- # DipaMed-1 **A language model specialised on Nigerian clinical guidelines.** DipaMed-1 adapts Meta's Llama-3.1-8B to Nigerian medicine, grounded in Federal Ministry of Health (FMOH) and Nigeria Centre for Disease Control (NCDC) clinical guidelines. It is built to give locally-appropriate clinical guidance that reflects Nigerian disease priorities, the Nigerian Essential Medicines List, and national treatment protocols. - **Developed by:** Destiny Ebhodaghe Ibhate (DipaHealth) - **Base model:** meta-llama/Llama-3.1-8B - **Language:** English - **License:** Llama 3.1 Community License > **Intended use:** clinical decision *support* for trained health workers. DipaMed-1 is **not** an autonomous diagnostic system and must not be used to make patient-care decisions without a qualified clinician. ## Highlights - where DipaMed-1 leads On [NigeriaMedQA](https://huggingface.co/datasets/DipaHealth/NigeriaMedQA), DipaMed-1 **outperforms its base model on the Nigeria-specific clinical topics it was built for:** | Topic | DipaMed-1 | Base Llama-3.1-8B | Improvement | |---|---|---|---| | Mental health | **95.8%** | 87.5% | **+8.3** | | Maternal emergencies | **90.6%** | 84.4% | **+6.2** | | Drug availability | **72.8%** | 67.0% | **+5.8** | | Hypertension | **68.5%** | 64.8% | **+3.7** | | Tuberculosis-HIV | **82.4%** | 79.4% | **+3.0** | | Lassa fever | **79.5%** | 76.9% | **+2.6** | | Sickle cell disease | **81.8%** | 80.0% | **+1.8** | | Outbreak diseases | **62.1%** | 60.3% | **+1.8** | These are the diseases and decisions that matter most in Nigerian practice. Across the full benchmark, DipaMed-1 performs comparably to the base model overall (76.3% vs 77.0%), while delivering these gains where Nigerian specialisation counts. ## What makes it different General medical models are trained on North American and European data. DipaMed-1 is grounded in **Nigerian** guidelines, giving Nigeria-appropriate answers a general model cannot: correct local first-line treatments, Essential-Medicines-List-aware choices, and NCDC/FMOH-aligned protocols. ## How it was built | Stage | Purpose | Data | |---|---|---| | **Continued pretraining** | Absorb Nigerian medical knowledge | 156 million words of Nigerian biomedical text (PubMed abstracts, open-access PMC full-text, clinical guidelines); approx. 254M tokens | | **Instruction tuning** | Learn to answer clinical questions | Q&A generated from and independently verified against real Nigerian guidelines, plus cleaned expert-created sources (PubMedQA, MedQA-USMLE, WikiDoc) | Training used QLoRA (rank 16), a learning-rate sweep with model selection on a **held-out validation set**, and completion-only loss masking. The evaluation benchmark was kept fully uncontaminated and used only once for final scoring. The pretraining corpus is not released; its construction methodology is described in the accompanying paper. ## Usage ```python import torch from transformers import AutoModelForCausalLM, AutoTokenizer model_id = "DipaHealth/DipaMed-1" model = AutoModelForCausalLM.from_pretrained(model_id, torch_dtype=torch.bfloat16, device_map="auto") tok = AutoTokenizer.from_pretrained(model_id) messages = [ {"role": "system", "content": "You are DipaMed-1, a clinical AI assistant grounded in Nigerian guidelines."}, {"role": "user", "content": "First-line treatment for uncomplicated malaria in a non-pregnant adult in Nigeria?"}, ] input_ids = tok.apply_chat_template(messages, add_generation_prompt=True, return_tensors="pt").to(model.device) out = model.generate(input_ids=input_ids, max_new_tokens=256, do_sample=False, pad_token_id=tok.eos_token_id) print(tok.decode(out[0][input_ids.shape[1]:], skip_special_tokens=True)) ``` ## Recommended deployment: retrieve, then answer (RAG) For production, wrap DipaMed-1 in a retrieval-augmented (RAG) pipeline over the Nigerian guidelines: retrieve the relevant passage, give it to the model, and have it answer **from that passage with a citation**. This substantially improves factual reliability, especially for exact drug doses where all language models are unreliable from memory, and lets the system cite its source. A dedicated DipaMed RAG service is planned as a separate release. ## Limitations and responsible use - **Exact doses:** do not rely on DipaMed-1 for precise dosing without retrieval support; language models do not reliably memorise numeric dose tables. - **Decision support only:** it assists clinicians and must not make autonomous clinical decisions. - **Scale:** at 8B parameters it will not match frontier models on general medicine; its strength is Nigerian domain specialisation. - **Errors and bias:** like all language models it can produce confident but incorrect answers; verify outputs against source guidelines. - **Scope:** English, text-only in this version. Speech and Nigerian-language support are planned. ## Citation ```bibtex @misc{dipamed2026, title = {DipaMed-1: A Nigerian Guideline-Specialised Clinical Language Model}, author = {Ibhate, Destiny Ebhodaghe}, year = {2026}, howpublished = {\url{https://huggingface.co/DipaHealth/DipaMed-1}} } ``` ## Acknowledgements Built on Meta Llama-3.1-8B. Evaluated with [NigeriaMedQA](https://huggingface.co/datasets/DipaHealth/NigeriaMedQA). Grounded in FMOH and NCDC clinical guidelines.